Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

Carfilzomib

(2013) K. M. Kortuem et al.   BLOOD

Primary proteasome inhibition results in cardiac dysfunction

(2013) Joerg Herrmann et al.   EUROPEAN JOURNAL OF HEART FAILURE

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database

(2013) Benjamin Honton et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

(2013) A Z Badros et al.   LEUKEMIA

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease

(2012) S. H. Armenian et al.   BLOOD

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

(2012) M. Alsina et al.   CLINICAL CANCER RESEARCH

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

(2012) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

Bortezomib-Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma

(2011) Ajay Gupta et al.   Cardiovascular Toxicology

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

(2011) J. Yang et al.   DRUG METABOLISM AND DISPOSITION

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

The role of the proteasome in heart disease

(2010) Yi-Fan Li et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Proteasome functional insufficiency activates the calcineurin–NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts

(2010) Mingxin Tang et al.   CARDIOVASCULAR RESEARCH

Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma

(2010) Hiroyuki Takamatsu et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Complete heart block secondary to bortezomib use in multiple myeloma

(2010) Constantin A Dasanu   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

The ubiquitin-proteasome pathway and endothelial (dys)function

(2009) K. Stangl et al.   CARDIOVASCULAR RESEARCH

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Proteasome inhibitors: Poisons and remedies

(2007) Silke Meiners et al.   MEDICINAL RESEARCH REVIEWS